Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery
Pain, Postoperative
About this trial
This is an interventional treatment trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- Fulfills NIH criteria for bariatric surgery
- Planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure
Exclusion Criteria:
- BMI <35 and > 60 kg/m2
- Inability to walk (bed-bound or wheelchair dependence)
Previous major abdominal surgery (possible adhesions and longer operation) defined as:
- open abdominal surgeries except simple appendectomy and common OB/GYN procedures in the pelvis (hysterectomy, C-section, and oophorectomy, tubal ligation)
- laparoscopic bowel or solid organ resection except laparoscopic cholecystectomy
- ventral hernia repair with mesh
- Preoperative chronic opiate use for chronic pain defined as opiate usage at least 60 mg/day of morphine equivalent for ≥ 3 months (as defined by International Association for the Study of Pain22) in the one year period prior to the bariatric surgery
- The American Society of Anesthesiologists (ASA) score > 3
- History of hypersensitivity or adverse reaction to bupivacaine or narcotics
- Inability to speak English
Concurrent surgical procedure including:
- ventral hernia repair
- Cholecystectomy
- hiatal hernia repair with posterior cruroplasty
- extensive lysis of adhesions
- other procedures that mandate addition of "trocar(s)" or "feeding tube"
- Addition of trocar(s) or conversion of surgery to hand-assisted or open
Sites / Locations
- Cleveland Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Experimental
Control
Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.